ETTX
NASDAQEntasis Therapeutics Holdings Inc.
Latest news
25 items- PREntasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary of Innoviva, Inc. (NASDAQ:INVA), today announced that six abstracts highlighting sulbactam-durlobactam (SUL-DUR) have been selected for presentation at IDWeek 2022, the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C. Details of the presentations are as follows: Oral Presentations: Title: Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: sulbactam-durlobactam
- SECSEC Form 15-12G filed by Entasis Therapeutics Holdings Inc.15-12G - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
- NEWSOver $42 Million Bet On This Biotechnology Stock? 4 Penny Stocks Insiders are BuyingUS producer prices likely to rise 0.8% on the month in June to match the previous month’s growth. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3 SeaChange International The Trade: SeaChange International, Inc. (NASDAQ:SEAC) 10% owner Karen Singer acquired a total of 424,942 shares at an avera
- INSIDERSEC Form 4: Innoviva, Inc. bought $42,395,047 worth of shares (19,270,476 units at $2.20)4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
- SECSEC Form EFFECT filed by Entasis Therapeutics Holdings Inc.EFFECT - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
- SECSEC Form EFFECT filed by Entasis Therapeutics Holdings Inc.EFFECT - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
- SECSEC Form EFFECT filed by Entasis Therapeutics Holdings Inc.EFFECT - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
- SECSEC Form EFFECT filed by Entasis Therapeutics Holdings Inc.EFFECT - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
- 13D/GSEC Form SC 13D/A filed by Entasis Therapeutics Holdings Inc. (Amendment)SC 13D/A - Entasis Therapeutics Holdings Inc. (0001724344) (Subject)
- SECSEC Form S-8 POS filed by Entasis Therapeutics Holdings Inc.S-8 POS - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
- SECSEC Form S-8 POS filed by Entasis Therapeutics Holdings Inc.S-8 POS - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
- SECSEC Form S-8 POS filed by Entasis Therapeutics Holdings Inc.S-8 POS - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
- SECSEC Form S-8 POS filed by Entasis Therapeutics Holdings Inc.S-8 POS - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
- SECSEC Form S-8 POS filed by Entasis Therapeutics Holdings Inc.S-8 POS - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
- SECSEC Form S-8 POS filed by Entasis Therapeutics Holdings Inc.S-8 POS - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
- SECSEC Form POS AM filed by Entasis Therapeutics Holdings Inc.POS AM - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
- SECSEC Form POS AM filed by Entasis Therapeutics Holdings Inc.POS AM - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
- SECSEC Form POS AM filed by Entasis Therapeutics Holdings Inc.POS AM - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
- SECSEC Form POS AM filed by Entasis Therapeutics Holdings Inc.POS AM - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
- SECEntasis Therapeutics Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
- INSIDERSEC Form 4: Wagner Kristie Ann returned 80,500 shares to the company, closing all direct ownership in the company4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
- INSIDERSEC Form 4: Triola Anna Diaz returned 125,000 shares to the company, closing all direct ownership in the company4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
- INSIDERSEC Form 4: Tommasi Ruben returned 150,000 shares to the company, closing all direct ownership in the company4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
- INSIDERSEC Form 4: Ronsheim Matthew returned 150,000 shares to the company, closing all direct ownership in the company4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
- INSIDERSEC Form 4: Perros Manoussos returned 478,500 shares to the company, closing all direct ownership in the company4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
ETTX FAQ
7 questionsWhat does Entasis Therapeutics Holdings Inc. do?
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated...Where does ETTX stock trade?
Entasis Therapeutics Holdings Inc. (ETTX) is listed on NASDAQ.What sector and industry is ETTX in?
Entasis Therapeutics Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Entasis Therapeutics Holdings Inc. go public?
Entasis Therapeutics Holdings Inc. (ETTX) completed its IPO in 2018.What are analysts saying about ETTX?
Entasis Therapeutics Holdings Inc. has had 4 recent analyst actions on file. The most recent action was from Wedbush: Neutral with a $180.00 price target on 2022-03-08. Recent price targets range from $180.00 to $700.00.What companies are similar to ETTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ETTX side-by-side with any of them on Quantisnow.How can I track ETTX on Quantisnow?
Quantisnow aggregates Entasis Therapeutics Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ETTX to receive live email and push alerts on every new disclosure.